/Abbvie%20Inc%20logo%20and%20stock%20chart-by%20IgorGolovniov%20via%20Shutterstock.jpg)
AbbVie Inc. (ABBV) is a worldwide biopharmaceutical company based in North Chicago, Illinois. It conducts research, develops, and supplies advanced medicines for the treatment of challenging conditions in immunology, cancer, neuroscience, ophthalmology, and aesthetics. The company has a market capitalization of $386.47 billion.
Strong sales from immunology blockbusters Skyrizi and Rinvoq offset Humira’s patent cliff decline. Growth in neuroscience and a diversified portfolio fueled revenue in 2025. Over the past 52 weeks, AbbVie’s stock has gained 25.8%, while over the past six months, it has risen 15.3%. The company’s shares reached a 52-week high of $244.81 in October 2025, but are down 10% from that level.
